News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2022 Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events Todd Neale April 04, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2021 ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI Yael L. Maxwell May 15, 2021
News Conference News ACC 2021 Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III Todd Neale May 15, 2021
News Conference News ACC 2020 Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair L.A. McKeown April 07, 2020
News Conference News ACC 2020 PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients Yael L. Maxwell March 29, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2017 Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients L.A. McKeown March 21, 2017
News Conference News ACC 2017 Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery Michael O'Riordan March 19, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017